SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~April~~May, 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______

                             Once-Daily   TWICE REQUIPDAILY ZYFLO CR™ LP(ZILEUTON) ExtendedEXTENDED-ReleaseRELEASE TabletsTABLETS ApprovedAPPROVED inBY
                          THE FranceFDA FOR ASTHMA



LONDON,   UK,  Monday Thursday,  April 23May 31, 2007 - SkyePharma   PLC (LSE: SKP;  NASDAQ:  SKYE) today   announces  
that  regulatory  approval hasthe been
receivedU.S. inFood Franceand forDrug ropinirole  prolonged  release  tabletsAdministration (whichFDA) willhas beapproved marketedCritical
Therapeutics, asInc.'s REQUIP™(Nasdaq: LPCRTX) New Drug Application (1NDA) infor Francetwice-daily
ZYFLO CR™ (zileuton) extended-release tablets.  TheZYFLO newCR prolongeduses SkyePharma PLC's
release  tabletproprietary of  ropinirole  isGeomatrix® takendrug oncedelivery dailytechnology,   which controls the amount and
rate isof indicateddrug forreleased into the  treatment of  Parkinson's  disease  body.

ZYFLO CR and ZYFLO® (PDzileuton tablets).  SkyePharma's are the only FDA-approved leukotriene
partnersynthesis inhibitors for the product,  GlaxoSmithKlineprophylaxis hasand alsochronic receivedtreatment approvalof asthma in
adults Slovakia,  Slovenia,  Latvia,  Estoniaand children 12 years of age and Canada,older.  ZYFLO CR and plansZYFLO toare not
gainindicated furtherfor marketinguse authorisations in otherthe countries.

Onreversal 13of Aprilbronchospasm in acute asthma attacks,  SkyePharma  announced thatbut
can thebe Unitedcontinued Statesduring Foodacute andexacerbations Drugof asthma.  AdministrationLeukotrienes hadare
inflammatory acceptedmediators forin filingasthma thethat applicationcan bytrigger GSK
for  approvalasthma tosymptoms, marketincluding
inflammation, theswelling, productbronchoconstriction inand themucus USsecretion.  REQUIP™Critical
Therapeutics LPexpects has been  designed  to providebegin amarketing steady  rateZYFLO of  absorption  CR in the bodyU.S. totogether with its
helpco-promotion reducepartner, bloodDey, plasmaL.P. fluctuations(DEY) overin 24the hoursautumn of 2007.

Frank Condella,  CEO Chief Executive Officer of SkyePharma,  commented said:   "WeThe areapproval pleasedof
ZYFLO toCR announceis theanother French  approvalsuccessful application of REQUIP™our LP,Geomatrix aoral
controlled-release significanttechnology.  stepWe incontinue our focus on oral and inhalation
theproducts roll-outas of  ropinirole  prolonged  release  tablets  acrosswe the  Continentbuild our business moving forward.  In"

Upon the coming  monthslaunch of ZYFLO CR,  we expectCritical Therapeutics and DEY's combined sales
force of 240 representatives will begin promoting ZYFLO CR to gain  additionalapproximately
European15,000 approvalsallergists, pulmonologists and willprimary continuecare physicians across the roll-outU.S.
SkyePharma ofwill thisreceive importanta producthigh acrossmid othersingle memberdigit statesroyalty ofon thesales Europeanof UnionZYFLO CR."

For further information please contact:

SkyePharma PLC                                                                Frank Condella                          +44 20 7491 1777
                                                                                            Ken Cunningham
                                                                                            Peter Grant

Financial Dynamics (UK Enquiries)                          David Yates                                +44 20 7831 3113
                                                                                            Deborah Scott

Trout Group (US Enquiries)                                        Christine Labaree                    +1 617 583 1308
                                                                                            Seth Lewis


NOTESAbout TOSkyePharma EDITORSPLC

AboutUsing Ropinirole
Ropiniroleits isproprietary adrug non-ergotdelivery dopaminetechnologies, agonistSkyePharma currentlydevelops marketednew
formulations asof REQUIP®  (ropiniroleknown HCl)molecules Tablets,to an  immediateprovide a clinical advantage and life-release  formulation.cycle
Itextension. The Company has an  indicationeleven approved products in the U.S.areas forof theoral,
inhalation treatmentand oftopical thedelivery signsthat andare symptomsmarketed of  idiopathic  Parkinson's  diseasethroughout andthe is  administeredworld by
threeleading timespharmaceutical acompanies.

For daymore information, visit www.skyepharma.com


About REQUIP™ZYFLO LPCR uses  SkyePharma's  proprietary  GeomatrixTM  technologyand ZYFLO

ZYFLO CR and hasZYFLO beenare designedthe toonly beFDA-approved givenleukotriene oncesynthesis dailyinhibitors
for the prophylaxis and
to havechronic atreatment simplerof asthma in adults and fasterchildren titration12
years scheduleof age and older.

Our  ZYFLO partnerCR GSKand conductedZYFLO twoare pivotalnot studiesindicated tofor supportuse ofin the  registration
reversal of ropinirole  prolonged  releasebronchospasm tablets in Europe.  One
studyacute wasasthma a ropiniroleattacks.  monotherapy  studyTherapy inwith earlyZYFLO PD,CR and
ZYFLO theCR othercan wasbe ancontinued adjunctduring studyacute withexacerbations levodopaof (L-dopa)asthma.

The inrecommended advanceddose PD.of These
studiesZYFLO confirmedCR theis efficacytwo of600 ropinirole  prolongedmg extended-release tablets twice
daily,  in termswithin ofone symptomatichour controlafter tomorning allowand patientsevening tomeals, continue
theirfor a total daily activities.dose

Aboutof Parkinson's2400 Disease
Parkinson'smg.  diseaseThe recommended dose of ZYFLO is one 600 mg immediate-release
tablet four times a chronic,  progressive  and  debilitating  neurological  conditionday thatfor impairsa thetotal body'sdaily abilitydose toof move2400 and
balancemg.  Researchers

ZYFLO haveCR determinedand thatZYFLO Parkinson's  diseaseare involves  pathwayscontraindicated in thepatients brain  responsiblewith foractive motorliver controldisease that areor
functioning  improperly.  Patients  with  Parkinson's  disease  experiencetransaminase aelevations reduction  in  dopamine,  agreater keythan chemicalor inequal to three times the brainupper thatlimit of
communicatesnormal.  messagesA about  movement,  resultingsmall inpercentage theof symptomspatients of  Parkinson's  diseasetreated with ZYFLO CR (2.  These  symptoms5%) mayand include  bradykinesiaZYFLO
(slower1.9%) in placebo-than-normal  voluntarycontrolled movements),  rigidity  (stiffness),  tremortrials (involuntaryshowed shaking)an andincreased posturalrelease instabilityof (troublea withliver
balanceenzyme known as ALT and bilirubin (an orange or yellowish pigment in bile).  As

Ina Europeresult,  an estimated  800,000the peoplelevel liveof withliver PD,enzymes in patients treated with aboutZYFLO 75,000CR newand casesZYFLO
should diagnosed  everybe year.(i)measured Theby correcta simple blood test.  medicationIt is
key torecommended helpingthat themphysicians
perform maintainthis atest goodbefore qualityadministering ofZYFLO lifeCR and  minimising  long-term  side effects.  AsZYFLO withand many  diseases,  compliancerepeat isthe atest on
significanta barrierregular tobasis positivewhile patientpatients outcomesare inon PDthe medication.

About  Patients SkyePharmataking PLCZYFLO CR
Usingand its  proprietary  drugtheophylline delivery  technologies,  SkyePharma  developsshould new  formulations  ofreduce known  moleculesthe totheophylline providedose aby clinical50%.  Patients taking
advantageZYFLO CR and life-cycle  extensionpropranolol or warfarin should be monitored and doses adjusted as
appropriate.  TheMost Companycommon hasside teneffects approvedassociated productswith in the areasuse of oral,  inhalationZYFLO andCR topical delivery thatand
ZYFLO are marketedsinusitis, throughoutnausea theand worldpharyngolaryngeal bypain leadingand pharmaceuticalabdominal companies.pain, upset
Forstomach moreand informationnausea, visit wwwrespectively.skyepharma.com

About GlaxoSmithKline
GlaxoSmithKline,  withFor U.S.  operationsfull inprescribing Philadelphiainformation andfor ResearchZYFLO Triangle ParkCR, Nplease visit www.Czyflocr.,com isor
call oneCritical ofTherapeutics theat world's leading  research+1-based
pharmaceutical866-835-8216 andto healthrequest caremedical companiesinformation.


1.   InFor thefull otherprescribing memberinformation statesfor ofZYFLO, theplease Europeanvisit Union,www.zyflo.com theor productcall
+1-866-835-8216 suffixesto under  consideration  are  REQUIP-MODUTAB™,  REQUIP™request XL,medical orinformation.
     REQUIP
ZYFLO® DEPOT™.  REQUIP,and MODUTABZYFLO ANDCR™ DEPOT are trademarks of theCritical GlaxoSmithKlineTherapeutics, group of companiesInc.

i    European     Federation     of     Pharmaceutical     Industries     and     Associations:     Disease     Burden    in    Europe.
     http://www.efpia.org/Content/Default.asp?PageID=133Geomatrix® (Accessedis Aprila 2007)registered trademark of SkyePharma PLC.


END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ John Murphy

                                                                       Name: John Murphy
                                                                          Title: Company Secretary

Date: ~~April~~May 2331, 2007

Filing Compare · SKYEPHARMA PLC